

# Anjali S Advani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7188599/publications.pdf>

Version: 2024-02-01

106  
papers

3,863  
citations

218677

26  
h-index

128289

60  
g-index

107  
all docs

107  
docs citations

107  
times ranked

3919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	1.4	39
2	G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. <i>Blood Advances</i> , 2022, , .	5.2	0
3	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosomeâ€“Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44
4	AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker. <i>Scientific Reports</i> , 2022, 12, 5809.	3.3	5
5	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.	5.2	10
6	Sequencing of novel agents in relapsed/refractory Bâ€“cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
7	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	1.3	5
8	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
9	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
10	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kitâ€“positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 113-118.	0.4	4
11	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
12	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
13	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	1.4	32
14	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
15	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	4.9	96
16	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	3.5	23
17	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.8	32
18	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	5.2	85

#	ARTICLE	IF	CITATIONS
19	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
20	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	6.2	34
21	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
22	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
23	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
24	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 189, 967-975.	2.5	10
25	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1943-1953.	1.3	2
26	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
27	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
28	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
29	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	4.1	210
30	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	5.2	34
31	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
32	<i>BCOR</i> and <i>BCORL1</i> mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1587-1590.	1.3	16
33	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2696-2696.	1.4	1
34	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	1.4	5
35	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). <i>Blood</i> , 2019, 134, 1281-1281.	1.4	0
36	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2650-2650.	1.4	1

#	ARTICLE	IF	CITATIONS
37	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. <i>Blood</i> , 2019, 134, 2595-2595.	1.4	1
38	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018, 8, 4.	6.2	43
39	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018, 59, 363-371.	1.3	4
40	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1831-1839.	1.6	112
41	Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. <i>International Journal of Hematologic Oncology</i> , 2018, 7, IJH02.	1.6	26
42	Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study. <i>Blood</i> , 2018, 132, 4031-4031.	1.4	1
43	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , 2018, 132, 4806-4806.	1.4	1
44	Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7028-7028.	1.6	2
45	Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7029-7029.	1.6	1
46	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2075-2075.	1.4	0
47	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1527-1527.	1.4	0
48	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018, 132, 371-371.	1.4	0
49	Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2017, 98, 425-434.	2.2	41
50	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
51	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	4.9	67
52	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	4.6	158
53	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.	5.2	103
54	Perspectives and Future Directions for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S6-S9.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	27.0	1,047
56	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2016, 128, 1659-1659.	1.4	2
57	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4336-4336.	1.4	8
58	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 591-591.	1.4	35
59	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 2536-2542.	1.3	18
60	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 489-495.	0.4	4
61	Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. <i>Future Oncology</i> , 2015, 11, 1729-1739.	2.4	10
62	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11047-11047.	1.6	1
63	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. <i>Blood</i> , 2015, 126, 1350-1350.	1.4	1
64	<scp>SWOG</scp>0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 233-237.	2.5	39
65	Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 172-177.e1.	0.4	5
66	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 504-509.	2.5	73
67	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). <i>Blood</i> , 2013, 122, 1555-1555.	1.4	1
68	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.	1.4	9
69	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. <i>Blood</i> , 2012, 120, 1696-1696.	1.4	3
70	Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 19-24.	1.3	5
71	Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). <i>British Journal of Haematology</i> , 2011, 153, 504-507.	2.5	11
72	A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 2600-2600.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 120-120.	1.4	0
74	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 2015-2015.	1.4	9
75	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities. <i>Blood</i> , 2011, 118, 4137-4137.	1.4	0
76	Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 776-7.	0.3	4
77	Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. <i>BMC Cancer</i> , 2010, 10, 387.	2.6	23
78	A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 1622-1626.	0.8	16
79	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 430-434.	2.5	57
80	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2085-2093.	1.6	306
81	OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 606-612.	1.3	17
82	A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 473-476.	0.4	14
83	A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010, 116, 332-332.	1.4	4
84	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. <i>Blood</i> , 2010, 116, 3076-3076.	1.4	0
85	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 1675-1675.	1.4	0
86	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. <i>Blood</i> , 2010, 116, 2736-2736.	1.4	0
87	Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 1012-1012.	1.4	1
88	The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 1043-1043.	1.4	0
89	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 4681-4681.	1.4	0
90	Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. <i>Leukemia Research</i> , 2008, 32, 913-918.	0.8	37

#	ARTICLE	IF	CITATIONS
91	Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1560-1566.	1.3	6
92	OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.. <i>Blood</i> , 2008, 112, 1486-1486.	1.4	0
93	High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.. <i>Blood</i> , 2008, 112, 1137-1137.	1.4	0
94	A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.. <i>Blood</i> , 2008, 112, 955-955.	1.4	0
95	Impact of Weekend Admissions on Quality of Care and Outcomes in Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2008, 112, 1942-1942.	1.4	0
96	Toxicities of Intravenous (IV) Pegasparginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2007, 110, 2811-2811.	1.4	9
97	Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).. <i>Blood</i> , 2006, 108, 4492-4492.	1.4	0
98	Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3069-3069.	1.4	0
99	FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications. <i>Current Pharmaceutical Design</i> , 2005, 11, 3449-3457.	1.9	22
100	Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2005, 106, 230-230.	1.4	19
101	Survival and Predictors of Outcome in Acute Leukemia Patients Admitted to the Intensive Care Unit.. <i>Blood</i> , 2005, 106, 2778-2778.	1.4	0
102	Cytogenetic Classification Systems and Overall Survival Following Bone Marrow Transplant (BMT) for Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 4500-4500.	1.4	0
103	CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 3292-3292.	1.4	0
104	Epsilon Aminocaproic Acid (EACA) Reduces Transfusion Requirements in Patients with Thrombocytopenic Hemorrhage.. <i>Blood</i> , 2004, 104, 3938-3938.	1.4	0
105	Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival.. <i>Blood</i> , 2004, 104, 1074-1074.	1.4	1
106	The Relationship between Weekend Admissions and Outcome in Older Adults with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2004, 104, 3140-3140.	1.4	0